Dual-Modality System for Imaging Colon Cancer in Mice

用于小鼠结肠癌成像的双模态系统

• 批准号: 6905572
• 负责人: Jennifer Kehlet Barton
• 金额: $ 30.96万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6905572
• 关键词: automated data processing; bioimaging /biomedical imaging; biomedical equipment development; colon neoplasms; computer data analysis; computer program /software; computer system design /evaluation; contrast media; early diagnosis; fluorescence; gastrointestinal imaging /visualization; genetically modified animals; high throughput technology; image enhancement; intestine neoplasm; laboratory mouse; lasers; methylhydrazines; miniature biomedical equipment; neoplasm /cancer radiodiagnosis; neoplastic growth; nonsteroidal antiinflammatory agent; optical tomography; phantom model; tissue /cell culture

DESCRIPTION (provided by applicant): The overall goal of this research is to create and apply a unique dual-modality system for time-series imaging of colon cancer development in mice. Miniaturized optical coherence tomography (OCT), laser induced fluorescence (LIF), and novel contrast agents are combined into a sensitive structural and biochemical imaging system. The minimally invasive nature of this system means that the development (and response to treatment) of each individual tumor can be tracked in vivo. This study is divided into 4 specific aims: 1. Design, build and test miniature combined OCTILIF catheters. We propose to build a high-throughput probe with ability to measure the entire lower colon with one insertion. Subsequently, we propose to build a large bandwidth catheter that supports very high resolution imaging. 2. Develop novel contrast agents for improved visualization of tumors. Contrast agents may help identify the earliest stages of carcinogenesis. We will investigate three classes: a) gold-coated nanoshells, which we have shown to have an extremely bright OCT signature, b) liposomes, which incorporate fluorescent dyes, and c) dietary cholorphyll, These agents will be tested in phantoms, cell cultures, and mouse models. 3. Perform studies of DMH-treated and MIN mice with and without contrast agents and NSAID administration. Two mouse models, DMH-treated and genetically altered multiple intestinal neoplasia (MIN) will be utilized in this specific aim. In a series of studies, the lower colon of these mice will be imaged every 3-6 weeks to evaluate tumorigenesis. The effect of non-steroidal anti-inflammatory agent (NSAID) preventive and therapeutic treatment will be assessed, as will enhancement of image contrast with the contrast agents in specific aim 2. 4. Develop analysis tools for interpreting OCT images and LIF spectra. Storage and retrieval software will be developed. For analyzing OCT images, texture analysis and automated layer thickness measurements will be used, and for LIF spectra, component analysis and intrinsic fluorescence extraction methods will be employed.

描述（由申请人提供）： 这项研究的总体目标是创建和应用独特的双模式系统，以用于小鼠结肠癌发展的时间序列成像。微型光学相干断层扫描（OCT），激光诱导的荧光（LIF）和新型的对比剂被合并为敏感的结构和生化成像系统。该系统的最低侵入性性质意味着可以在体内跟踪每个肿瘤的发育（和对治疗的反应）。这项研究分为4个具体目标：1。设计，构建和测试微型八核导管。我们建议建立一个高通量探针，具有一个插入的能力，可以测量整个下结肠。随后，我们建议建立一个支持非常高分辨率成像的大带宽导管。 2。发​​展新型的对比剂，以改善肿瘤的可视化。对比剂可能有助于确定癌变的最早阶段。我们将研究三个类：a）涂有金色的纳米壳，我们已证明其具有非常明亮的OCT签名，b）脂质体，其中掺有荧光染料，c）饮食中胆固醇，这些药物将在幻影，细胞培养物和小鼠模型中进行测试。 3.对具有和没有对比剂和NSAID给药的DMH处理和最小小鼠进行研究。在此特定目的中，将利用两种小鼠模型，分别经过DMH处理和遗传改变的多个肠道肿瘤（min）。在一系列研究中，这些小鼠的下结肠将每3-6周成像以评估肿瘤发生。将评估非甾体类抗炎药（NSAID）预防和治疗治疗的影响，图像对比度的对比度也将增强特定目标2。4。开发解释OCT图像和LIF光谱的分析工具。将开发存储和检索软件。为了分析OCT图像，将使用纹理分析和自动层厚度测量，并将采用LIF光谱，组件分析和内在的荧光提取方法。